The much-touted arrival of "precision medicine" promises tailored technologies that help individuals and may also reduce health care costs. New research shows how pregnancy screening can meet both of ...

A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of ...

The bulk of cfDNA research is founded upon DNA originating from cancer cells. Circulating tumor DNA (ctDNA) are nucleic biomarkers used to detect or monitor the advancement of cancer over time. These ...

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc.

Cell-free DNA (cfDNA) refers to fragments of DNA circulating in the bloodstream that originate from various sources, including dead or dying cells. In recent years, cfDNA has emerged as a promising ...

Researchers found that maternal plasma cell-free DNA methylation patterns in late pregnancy were associated with later autism ...

AUSTIN, Texas, April 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived ...

Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication posing significant health risks to both mothers and their newborns. Early detection and treatment of GDM are crucial to ...

cfDNA detects obesity, diabetes, and liver disease early Tracks inflammation and metabolic changes over time A promising alternative to invasive tests like biopsies Metabolic diseases, like obesity, ...